Clinical trials: Anthrax
Anthrax
Anthrax Vaccine Clinical Trials
This study will examine the recombinant, that is, produced by genetic engineering, protective antigen (rPA) that brings about antibodies to neutralize the anthrax toxin and that could therefore be predicted to offer protection…
- Trial name
- NCT00114621
- Testing
- Anthrax Vaccine, Blood Chemistry, Hematology
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Inhalational Anthrax
Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
To evaluate the safety and tolerability and pharmacokinetics (PK) of a single intravenous (IV) dose of ETI-204 in adult volunteers.
- Trial name
- NCT01929226
- Testing
- ETI-204
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Elusys Therapeutics
Anthrax
A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults
This study will provide preliminary safety and comparative immunogenicity data for the E.coli derived rPA vaccine administered by intramuscular (IM) injection at Day 0 and Month 1.Doses will range from 5 μg to 100 μg rPA, and at…
- Trial name
- NCT00057525
- Testing
- Anthrax, Alhdryogel or PBS
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
Lung Cancer
Charcoal in Lung Cancer Patients Undergoing TEMLA
This proof-of-concept study serves as the preliminary step to prove safety of oral activated charcoal (OAC) in patients with solid tumors before moving to a hematologic malignancy patient population.
- Trial name
- NCT04928950
- Testing
- Activated charcoal
- Sponsor
- Masonic Cancer Center, University of Minnesota
Nephrology
The Effect of AC-134 in Chronic Kidney Diseases
The objective is to explore the effects of adding AC-134 on renal function, proteinuria, uremic toxins, and metabolism-related markers in chronic kidney disease.
- Trial name
- NCT06441435
- Testing
- Low protein diet with AC-134, Standard treatment
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Taichung Veterans General Hospital
Anthrax
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
Primary: To compare the safety profile of a single intravenous administration of AVP-21D9 as compared with Placebo Secondary: To evaluate the pharmacokinetics (PK) of a single intravenous administration of AVP-21D9 To evaluate…
- Trial name
- NCT01202695
- Testing
- AVP-21D9
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Ischemic Stroke, Malignant Edema
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
This is a randomized, multi-center, prospective, double blind study. The primary objective is to assess the efficacy and safety of glyburide (RP-1127) compared to placebo in participants with a severe anterior circulation…
- Trial name
- GAMES-RP (NCT01794182)
- Testing
- Glyburide for Injection
- Where
- 17 sites in United States
- Volunteers
- 86 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Healthy Adult Volunteers
A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers
This is a pilot study designed to test feasibility, tolerability, and safety of medical grade oral Activated Charcoal (AC) in 12 healthy volunteers. To determine the two most palatable and tolerable AC combinations.
- Trial name
- NCT04204772
- Testing
- Activated charcoal and Tap Water, Activated Charcoal and Apple Juice
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Anthrax
Anthrax AV7909 Boost Evaluation Study
This randomized, phase 2, double-blinded, multicenter study is designed to assess the safety and immune response kinetics of CYFENDUS™ (henceforth AV7909) administered on 2 primary series vaccination schedules followed by 6- and…
- Trial name
- ABESt (NCT05997264)
- Testing
- AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL)
- Where
- 7 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Symptoms of Inhalational Anthrax
Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum
The purpose of the study is to assess the pharmacokinetics of three doses of NP-015 (210, 420 or 840 units TNA) in healthy volunteers. To evaluate the safety of NP-015 based on adverse events and laboratory assessments.
- Trial name
- NCT00448253
- Testing
- NP-015
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Healthy Participants
A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants
The purpose of this study is to evaluate the effects of co-administration of activated charcoal with sorbitol on the single-dose drug levels of mavacamten in healthy participants.
- Trial name
- NCT05320094
- Testing
- Mavacamten, Activated Charcoal with Sorbitol
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Smoking ( Cigarette)
Cigarette Filter Study
The overall purpose of this study is to determine the effects of using charcoal-filtered cigarettes on product perceptions, smoking behaviors, and biomarkers of exposure to tobacco-related toxicants.
- Trial name
- NCT07348679
- Testing
- Charcoal filtered cigarettes with marketing, Charcoal filtered cigarette without marketing, Non-charcoal filtered cigarettes
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- Rutgers, The State University of New Jersey
Anthrax
Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
This study will determine the safety and PK of a single IV dose of ETI-204 in subjects 18 to 65 years of age. Three cohorts will be studied with subjects receiving ETI-204.
- Trial name
- NCT01453907
- Testing
- ETI-204, "Anthim"
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Elusys Therapeutics
Study is Being Conducted in Healthy Volunteers
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and without a spacer device.
- Trial name
- NCT02934607
- Testing
- Symbicort pMDI with spacer device, Symbicort pMDI without spacer device
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Anthrax
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
The purpose of this study is to: evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) as compared with either 90 mg/kg, 180 mg/kg or 360…
- Trial name
- NCT00845650
- Testing
- AIGIV 3.5 mg/kg, Gamunex 90 mg/kg, AIGIV 7.0 mg/kg
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Anticoagulants; Circulating, Hemorrhagic Disorder
Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
This is a prospective, multicentric, randomized, open labeled superiority trial This study aims to evaluate the efficacy of oral activated charcoal for improving elimination of direct oral anticoagulants ( Rivaroxaban, Apixaban)…
- Trial name
- CACAOD (NCT02969746)
- Testing
- Activated Charcoal
- Where
- 6 sites in France
- Sponsor
- University Hospital, Angers
Anthrax
Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin
This protocol is a joint project of the National Institutes of Health, the Centers for Disease Control and the United States Army Medical Research Institute for Infectious Diseases.
- Trial name
- NCT00031291
- Testing
- Anthrax Immune Globulin
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Bacillus Anthracis (Anthrax)
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule
A Phase IV, randomized, multicenter trial to assess the immunogenicity and safety of BioThrax® in varying dose regimens with the primary objective of obtaining information on possible dose-sparing strategies in the event of a…
- Trial name
- NCT01641991
- Testing
- BioThrax®
- Where
- 4 sites in United States
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Inhalational Anthrax
Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin
- Trial name
- NCT01952444
- Testing
- ETI-204, Ciprofloxacin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Elusys Therapeutics
Bacillus Anthracis (Anthrax)
Monoclonal Antibody for Treatment of Inhalation Anthrax
The purpose of this study is to evaluate the safety and pharmacokinetics (how long a drug stays in the bloodstream and how high the levels of the drug are at different times) of ETI-204 following intravenous (IV-into a vein)…
- Trial name
- NCT00138411
- Testing
- Ciprofloxacin 500 mg, ETI-204 (Anthim)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)